206 related articles for article (PubMed ID: 11261808)
1. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR.
Samochocki M; Zerlin M; Jostock R; Groot Kormelink PJ; Luyten WH; Albuquerque EX; Maelicke A
Acta Neurol Scand Suppl; 2000; 176():68-73. PubMed ID: 11261808
[TBL] [Abstract][Full Text] [Related]
2. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.
Samochocki M; Höffle A; Fehrenbacher A; Jostock R; Ludwig J; Christner C; Radina M; Zerlin M; Ullmer C; Pereira EF; Lübbert H; Albuquerque EX; Maelicke A
J Pharmacol Exp Ther; 2003 Jun; 305(3):1024-36. PubMed ID: 12649296
[TBL] [Abstract][Full Text] [Related]
3. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system.
Santos MD; Alkondon M; Pereira EF; Aracava Y; Eisenberg HM; Maelicke A; Albuquerque EX
Mol Pharmacol; 2002 May; 61(5):1222-34. PubMed ID: 11961141
[TBL] [Abstract][Full Text] [Related]
4. The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca2+ signals and neurotransmitter release.
Dajas-Bailador FA; Heimala K; Wonnacott S
Mol Pharmacol; 2003 Nov; 64(5):1217-26. PubMed ID: 14573772
[TBL] [Abstract][Full Text] [Related]
5. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
[TBL] [Abstract][Full Text] [Related]
6. Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology.
Coyle JT; Geerts H; Sorra K; Amatniek J
J Alzheimers Dis; 2007 Jul; 11(4):491-507. PubMed ID: 17656829
[TBL] [Abstract][Full Text] [Related]
7. Cholinergic modulation by opioid receptor ligands: potential application to Alzheimer's disease.
Motel WC; Coop A; Cunningham CW
Mini Rev Med Chem; 2013 Mar; 13(3):456-66. PubMed ID: 22931533
[TBL] [Abstract][Full Text] [Related]
8. α4 nicotinic acetylcholine receptor modulated by galantamine on nigrostriatal terminals regulates dopamine receptor-mediated rotational behavior.
Inden M; Takata K; Yanagisawa D; Ashihara E; Tooyama I; Shimohama S; Kitamura Y
Neurochem Int; 2016 Mar; 94():74-81. PubMed ID: 26911419
[TBL] [Abstract][Full Text] [Related]
9. Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors.
Takata K; Kitamura Y; Saeki M; Terada M; Kagitani S; Kitamura R; Fujikawa Y; Maelicke A; Tomimoto H; Taniguchi T; Shimohama S
J Biol Chem; 2010 Dec; 285(51):40180-91. PubMed ID: 20947502
[TBL] [Abstract][Full Text] [Related]
10. Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems.
Noda Y; Mouri A; Ando Y; Waki Y; Yamada SN; Yoshimi A; Yamada K; Ozaki N; Wang D; Nabeshima T
Int J Neuropsychopharmacol; 2010 Nov; 13(10):1343-54. PubMed ID: 20219155
[TBL] [Abstract][Full Text] [Related]
11. Nicotinic cholinergic modulation: galantamine as a prototype.
Woodruff-Pak DS; Lander C; Geerts H
CNS Drug Rev; 2002; 8(4):405-26. PubMed ID: 12481195
[TBL] [Abstract][Full Text] [Related]
12. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease.
Maelicke A; Albuquerque EX
Eur J Pharmacol; 2000 Mar; 393(1-3):165-70. PubMed ID: 10771010
[TBL] [Abstract][Full Text] [Related]
13. Galantamine activates muscle-type nicotinic acetylcholine receptors without binding to the acetylcholine-binding site.
Akk G; Steinbach JH
J Neurosci; 2005 Feb; 25(8):1992-2001. PubMed ID: 15728839
[TBL] [Abstract][Full Text] [Related]
14. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease.
Maelicke A; Samochocki M; Jostock R; Fehrenbacher A; Ludwig J; Albuquerque EX; Zerlin M
Biol Psychiatry; 2001 Feb; 49(3):279-88. PubMed ID: 11230879
[TBL] [Abstract][Full Text] [Related]
15. Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits.
Geerts H; Guillaumat PO; Grantham C; Bode W; Anciaux K; Sachak S
Brain Res; 2005 Feb; 1033(2):186-93. PubMed ID: 15694923
[TBL] [Abstract][Full Text] [Related]
16. Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors.
Arias E; Gallego-Sandín S; Villarroya M; García AG; López MG
J Pharmacol Exp Ther; 2005 Dec; 315(3):1346-53. PubMed ID: 16144975
[TBL] [Abstract][Full Text] [Related]
17. Galantamine is not a positive allosteric modulator of human α4β2 or α7 nicotinic acetylcholine receptors.
Kowal NM; Ahring PK; Liao VWY; Indurti DC; Harvey BS; O'Connor SM; Chebib M; Olafsdottir ES; Balle T
Br J Pharmacol; 2018 Jul; 175(14):2911-2925. PubMed ID: 29669164
[TBL] [Abstract][Full Text] [Related]
18. Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors.
Schilström B; Ivanov VB; Wiker C; Svensson TH
Neuropsychopharmacology; 2007 Jan; 32(1):43-53. PubMed ID: 16641937
[TBL] [Abstract][Full Text] [Related]
19. Localization by site-directed mutagenesis of a galantamine binding site on α7 nicotinic acetylcholine receptor extracellular domain.
Ludwig J; Höffle-Maas A; Samochocki M; Luttmann E; Albuquerque EX; Fels G; Maelicke A
J Recept Signal Transduct Res; 2010 Dec; 30(6):469-83. PubMed ID: 21062106
[TBL] [Abstract][Full Text] [Related]
20. Galantamine hydrobromide: an agent for Alzheimer's disease.
Zarotsky V; Sramek JJ; Cutler NR
Am J Health Syst Pharm; 2003 Mar; 60(5):446-52. PubMed ID: 12635450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
